GMED GMED グロ―バス・メディカル

New York, USA, April 26, 2022 (GLOBE NEWSWIRE) -- The Global Joint Reconstruction Devices Market is Anticipated to Surpass USD 27 Million with a CAGR of 6.05% by 2026, Assesses DelveInsight The Joint Reconstruction Devices market is witnessing immense growth due to the factors such as the increasing prevalence of arthritis, and musculoskeletal ailments along with the rising number of orthopedic surgeries, among others. According to the latest report published by DelveInsight, " Joint Reconstruction Devices Market Insight , the global Joint Reconstruction Devices market is expected to witness significant growth owing to an increase in the prevalence of arthritis and musculoskeletal ailments. Furthermore, the rising number of orthopedic surgeries in the developed regions, the rising prevalence of bone degenerative diseases, gout, and the technological advancements offered by the Joint Reconstruction Devices is also a major factor contributing to the Joint Reconstruction Devices market growth.

The company''s CEO unexpectedly resigned.

Futures Drop With Traders On Edge Over Hawkish Central Banks US equity futures extended their Thursday losses, and were slightly lower on Friday morning as investors fretted over the latest hawkish remarks from Jerome "Crash Stonks" Powell. Nasdaq 100 futs were down 0.1% by at 7:15a.m. EDT after the underlying gauge slumped 2% on Thursday after Powell outlined his most aggressive approach yet to taming inflation, potentially endorsing two or more half percentage-point interest-rate increases, which prompted the market to price in more than six 25bps rate hike by the end of July and 10 hikes by the end of 2022. Shorter-dated Treasury yields surged. The dollar rose to the highest level since July 2020 amid losses for the British pound with data showing the U.K.’s cost-of-living crisis is hampering consumer spending. The overnight weakness pushed both S&P 500 futures lower by about 0.2% after cash closed down 1.5% Thursday, although trade was muted and range-bound. The fears over rising rates have been particularly damaging for frothy growth and technology parts of the market amid concerns about the squeeze on their future earnings. “The problem for the equity market and particularly those rate sensitive long duration stocks is they are simply not valued appropriately for that new regime, ” said Roger Lee, head of U.K. equity strategy at Investec. “Investors have been so heavily concentrated in those ‘growth’ parts of the market that the unwind and repositioning as this new rate environment sinks in could take months, if not years.” “Equities are really torn between these two forces right now and the first one is that earnings are actually pretty good,” Anastasia Amoroso, chief investment strategist at iCapital Securities LLC, said on Bloomberg Television.

Globus Medical Inc (NYSE: GMED ) announced the resignation of President and CEO Dave Demski after nearly 20 years with the company, with the last four and a half years as its CEO. The Board of Directors has named Daniel Scavilla as the company''s President and CEO, effective immediately. Dave will remain with … Full story available on Benzinga.com

Globus Medical (GMED) President and CEO, Dave Demski resigns after nearly 20 years with the company, with the last four and a half years as its CEO.

New York, USA, April 26, 2022 (GLOBE NEWSWIRE) -- The Global Joint Reconstruction Devices Market is Anticipated to Surpass USD 27 Million with a CAGR of 6.05% by 2026, Assesses DelveInsight The Joint Reconstruction Devices market is witnessing immense growth due to the factors such as the increasing prevalence of arthritis, and musculoskeletal ailments along with the rising number of orthopedic surgeries, among others. According to the latest report published by DelveInsight, " Joint Reconstruction Devices Market Insight , the global Joint Reconstruction Devices market is expected to witness significant growth owing to an increase in the prevalence of arthritis and musculoskeletal ailments. Furthermore, the rising number of orthopedic surgeries in the developed regions, the rising prevalence of bone degenerative diseases, gout, and the technological advancements offered by the Joint Reconstruction Devices is also a major factor contributing to the Joint Reconstruction Devices market growth.

The company''s CEO unexpectedly resigned.

Futures Drop With Traders On Edge Over Hawkish Central Banks US equity futures extended their Thursday losses, and were slightly lower on Friday morning as investors fretted over the latest hawkish remarks from Jerome "Crash Stonks" Powell. Nasdaq 100 futs were down 0.1% by at 7:15a.m. EDT after the underlying gauge slumped 2% on Thursday after Powell outlined his most aggressive approach yet to taming inflation, potentially endorsing two or more half percentage-point interest-rate increases, which prompted the market to price in more than six 25bps rate hike by the end of July and 10 hikes by the end of 2022. Shorter-dated Treasury yields surged. The dollar rose to the highest level since July 2020 amid losses for the British pound with data showing the U.K.’s cost-of-living crisis is hampering consumer spending. The overnight weakness pushed both S&P 500 futures lower by about 0.2% after cash closed down 1.5% Thursday, although trade was muted and range-bound. The fears over rising rates have been particularly damaging for frothy growth and technology parts of the market amid concerns about the squeeze on their future earnings. “The problem for the equity market and particularly those rate sensitive long duration stocks is they are simply not valued appropriately for that new regime, ” said Roger Lee, head of U.K. equity strategy at Investec. “Investors have been so heavily concentrated in those ‘growth’ parts of the market that the unwind and repositioning as this new rate environment sinks in could take months, if not years.” “Equities are really torn between these two forces right now and the first one is that earnings are actually pretty good,” Anastasia Amoroso, chief investment strategist at iCapital Securities LLC, said on Bloomberg Television.

Globus Medical Inc (NYSE: GMED ) announced the resignation of President and CEO Dave Demski after nearly 20 years with the company, with the last four and a half years as its CEO. The Board of Directors has named Daniel Scavilla as the company''s President and CEO, effective immediately. Dave will remain with … Full story available on Benzinga.com

Globus Medical (GMED) President and CEO, Dave Demski resigns after nearly 20 years with the company, with the last four and a half years as its CEO.

Globus Medical Inc. (NYSE:GMED) concluded the trading at $76.35 on Friday, April 08 with a rise of 0.53% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $75.95 and 5Y monthly beta was reading 1.09 with its price kept floating in the … Globus Medical Inc. (GMED) Forecast: Revisiting The Past To Gain Insights For The Future Read More »

Pune, April 07, 2022 (GLOBE NEWSWIRE) -- Orthopedic implants are medical devices which are used to support or replace damaged joints or bones. These implants are fabricated using several materials, namely titanium, stainless steel, and other plastic materials. These implants play a vital role in addressing several musculoskeletal conditions, by restoring mobility and reducing pain. Moreover, these implants further assists in treating deformities, restore normal skeletal function and stabilizing body posture among others. Orthopedic Implants Market by Regions The global market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the market of orthopedic implants, followed by Europe and Asia Pacific. North America will continue to dominate the global market in the forecast period owing to factors such as increasing incidences of musculoskeletal disorders, growing geriatric population and availability of advanced implant products. However, Asia Pacific is expected to witness the highest CAGR, with the growth in this market centered at China, Korea, Japan and India.

Analysts have provided the following ratings for Globus Medical (NYSE: GMED ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 1 0 0 3M Ago 0 1 1 0 0 In the last 3 months, 6 analysts have offered 12-month price targets for Globus Medical. The company has an average price target of $81.83 with a high of $91.00 and a low of $74.00. Below is a summary of how these 6 analysts rated Globus Medical over the past 3 months. The greater the number of bullish ratings, the more … Full story available on Benzinga.com

Wells Fargo initiated medical device company Globus Medical (GMED) with an overweight rating based on the companys market growth and share gains, as well as EBITDA margin.